Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04923529
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-10
First Post:
2021-06-06
Brief Title:
TAS-102 in Patients With Advanced Refractory Pancreatic Adenocarcinoma
Sponsor:
The University of Hong Kong
Organization:
The University of Hong Kong
Study Overview
Official Title:
Phase II Trial of TAS-102 in Patients With Advanced Refractory Pancreatic Adenocarcinoma
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a prospective phase II single arm mono-institutional study conducted in Queen Mary Hospital Hong Kong assessing the efficacy and safety of TAS 102 in advanced or metastatic pancreatic cancer patients
Detailed Description:
All the patients must be registered with the Investigators prior to initiation of treatment The registration desk will confirm all eligibility criteria and obtain essential information including patient number
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None